longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Teva Pharmaceutical Industries

TEVA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 66.39, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 54/256, the industry Median -1.36.

66.39xP/E
$40.22Stock price
$0.61Earnings per share
66.39xP/E
Stock price$40.22Earnings per share$0.61

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
26.76x
Typical range
24.22x–51.31x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TEVAUSTeva Pharmaceutical Industries
66.39x42.36%$46.87B
PCRXUSPacira BioSciences
69.60x629.69%$1.02B
IBOUSImpact BioMedical
61.03x--$48.27M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.